spacer
home > ict > spring 2008 > the fibrotic process
PUBLICATIONS
International Clinical Trials

The Fibrotic Process

Assessing liver fibrosis in clinical trials, William Rosenberg of University College London points to the impact made by individual direct markers

Chronic liver disease is now the second most common cause of death in middle-aged men and the fifth most common cause of death in the UK overall. Out of the top five causes of death it is the only disease that is increasing. The pharmaceutical and biotechnology industries are recognising the worldwide impact of chronic viral hepatitis, alcoholic liver disease and non-alcoholic fatty liver disease (NAFLD) as well as the earning potential for new therapeutic interventions and diagnostic tests. The development of new drugs in particular is dependent on the availability of biomarkers that permit the earliest possible ‘go/no-go’ decisions and provide evidence of efficacy which ensure that drug development is rapid, efficient and safe.

The clinical impact of all chronic liver diseases (CLD) can be attributed to liver fibrosis that may progress to cirrhosis, which in turn results in the complications of portal hypertension (bleeding varices, ascites or encephalopathy), liver failure, hepatocellular cancer and death or liver transplantation. It has been recognised for decades that interventions directed at the causes of CLD can reverse the consequences of liver disease by reversing liver fibrosis. This has been established in clinical trials for the use of anti-viral agents for hepatitis B or hepatitis C, for life modifications including abstinence from alcohol and weight reduction and is integral to the investigation of drugs targeting insulin resistance that underlies NAFLD.

Now, insights into the biology of liver fibrosis have created the possibility of developing anti-fibrotic drugs that target hepatic stellate cells that are central to the production and degradation of liver matrix in fibrosis. The development of this new class of drugs targeted at the fibrotic process rather than individual causes of CLD that have broad applicability, is dependent on accurate biomarkers that are fit for purpose for use in clinical trials.

LIVER BIOPSY

For almost half a century the liver biopsy has been regarded as the standard method for assessing liver fibrosis. Careful histological examination of a biopsy by an expert pathologist remains a vital asset in the diagnosis of liver disease. However, the place of liver biopsy in the assessment of liver fibrosis is increasingly questioned. Recent research has shown that liver biopsy is associated with many problems. For the patient and funder it is painful, hazardous and costly.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor William Rosenberg founded iQur Ltd in 2003, a biotechnology company specialising in diagnostic testing for hepatitis C and other chronic liver diseases. An active academic clinician, he is Deputy Director of the Institute of Hepatology at University College London. He is an experienced Chief Investigator in many multicentre clinical trials and studies investigating diagnostic tests. As Deputy Director of UKCRN, William leads on experimental medicine, a role that aims to ensure that developments in basic science can feed through into clinically relevant research and provide new insights into basic science.
spacer
Professor William Rosenberg
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Why You Should Be Using Ultrasonic Cleaning

Natoli Engineering Company, Inc.

Clean punches and dies are essential to maintaining the integrity and efficiency of your tooling investment, as well as the quality of your product. Ultrasonic cleaning has long been considered the most effective, nondestructive way to clean tools – from medical instruments to tablet tooling. The Tableting Specification Manual (TSM) states, “An ultrasonic bath is ideal for cleaning tooling.” This high-tech cleaning process also saves time, reduces cost and is better for the environment.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement